ChemicalBook CAS DataBase List Onartuzumab

Onartuzumab

Product NameOnartuzumab
CAS1133766-06-9
CBNumberCB28080831
MW0
MOL FileMol file
MSDS FileSDS

Chemical Properties

form	Liquid
color	Colorless to light yellow
FDA UNII	MS1J9720WC
NCI Drug Dictionary	onartuzumab

Onartuzumab Price

Product number	Packaging	Price	Product description	Buy
ChemScene CS-0612544	1mg	$320	Onartuzumab 99.62%	Buy
ChemScene CS-0612544	5mg	$1029	Onartuzumab 99.62%	Buy
ChemScene CS-0612544	10mg	$1625	Onartuzumab 99.62%	Buy
ChemScene CS-0612544	25mg	$3142	Onartuzumab 99.62%	Buy
aablocks AA0294SF	1mg	$215	Onartuzumab	Buy

Onartuzumab Chemical Properties,Usage,Production

Description

Onartuzumab is a monoclonal antibody that blocks the binding of HGF to the MET receptor.

Uses

Onartuzumab (MetMAb) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity[1].

Clinical Use

Onartuzumab is ineffective in improving clinical outcomes in (i) combination with current first-line chemotherapy in advanced nonsquamous cell NSCLC , (ii) combination with erlotinib in previously treated stage IIIB or IV NSCLC patients (Phase III) , and (iii) combination with platinum-doublet chemotherapy in advanced squamous cell NSCLC (Phase II) .

in vivo

Onartuzumab (30 mg/kg, IP, twice a week for 2 mouth) suppresses tumor growth^[3].

Animal Model:	Human HGF-transgenic SCID mice implanted with BxPC3 tumor cells, nude (nu/nu) mice implanted with KP4 human pancreatic xenograft tumor cells^[3]
Dosage:	30 mg/kg
Administration:	IP, twice a week for 2 mouth
Result:	Suppressed tumor growth, but did not affect the mean in vivo human HGF levels.

Animal Model:	U-87 MG tumor-bearing mice^[3]
Dosage:	30 mg/kg
Administration:	IP, once
Result:	Resulted in profound TGI (tumor growth inhibition) with 4/10 mice demonstrating a partial response (>50% reduction in tumor size) and 6/10 mice demonstrating a complete response (100% tumor regression).

References

[1] Merchant M, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96. DOI:10.1073/pnas.1302725110
[2] Prell RA, et al. Placental and Fetal Effects of Onartuzumab, a Met/HGF Signaling Antagonist, When Administered to Pregnant Cynomolgus Monkeys. Toxicol Sci. 2018 Sep 1;165(1):186-197. DOI:10.1093/toxsci/kfy141

Preparation Products And Raw materials

Onartuzumab Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
BOC Sciences	1-631-485-4226; 16314854226	info@bocsci.com	United States	9920	65
Shanghai YuanYe Biotechnology Co., Ltd.	18916372613	yanzihan@shyuanye.com	China	87240	60
ShangHai Biochempartner Co.,Ltd	177-54423994 17754423994	2853530910@QQ.com	China	7998	62
TargetMol Chemicals Inc.	+1-781-999-5354; +1-00000000000	marketing@targetmol.com	United States	32431	58
Wuhan Chemstan Biotechnology Co., Ltd.	027-65317797 15926423062	422450190@qq.com	China	10302	58
Beijing Jin Ming Biotechnology Co., Ltd.	010-60605840	psaitong@jm-bio.com	China	27626	58
TargetMol Chemicals Inc.	4008200310 15002144251	marketing@tsbiochem.com	China	24951	58
Biolab Reagents	027-65279366 18108604356	products@biolabreagent.com	China	9864	58
Wuhan Jingkangen Biomedical Technology Co., Ltd	13720134139 086-15871494362 13720134139	orders@jknbiochem.com	China	7284	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11963	58

View Latest Prices from Onartuzumab manufacturers

1133766-06-9, OnartuzumabRelated Search

Send Inquiry